Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
AION-JSW bid for Monnet Ispat gets NCLT nod

9h livemint
Mumbai: The National Company Law Tribunal (NCLT) has approved the bid of AION Capital-JSW Steel to acquire Monnet Ispat & Energy Ltd, providing major relief to the consortium.
500470 DB TTST TATASTEEL TATLY 500228 BHUSANSTL JSWSTEEL 500055 SBAZ

0
NCLT approves Aion-JSW Steel plan for Monnet Ispat

10h moneycontrol
The National Company Law Tribunal (NCLT) has given its approval for Monnet Ispat’s acquisition by the Aion Capital-JSW Steel consortium.
500228 JSWSTEEL

0
JSW Steel Limited - Updates

12h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500228 JSWSTEEL

0
Pursuing growth opportunities, but with prudence: Sajjan Jindal

19h moneycontrol
Even as JSW Steel embarks on an ambitious plan to expand capacity in India and overseas, it will adhere to conservative financial policies, said its top official.
500470 TTST TATASTEEL TATLY 500228 BHUSANSTL JSWSTEEL 500055

0
JSW Steel to double Dolvi capacity to 10 mtpa by 2019

2018-07-18 moneycontrol
JSW Steel Ltd today said its domestic expansion was well on track at its Dolvi unit in Maharashtra, which would double capacity to 10 million tonnes per annum at an estimated cost of Rs 15,000 crore by the end of 2019.
500228 JSWSTEEL

3
How Tata Steel is reversing its sunk cost fallacy

2018-07-18 moneycontrol
The world’s most astute investor and businessman Warren Buffett once admitted to losing a huge sum of money letting sunk cost fallacy (infusing more and more capital to salvage an original investment) play out by keeping alive the loss-making textile business of Berkshire Hathaway. He eventually rectified the mistake and gradually moved capital to more profitable and viable businesses.
BRK.A 500470 TTST TATASTEEL TATLY 500228 JSWSTEEL

0
NCLAT stops Bhushan Power Steel lenders from voting on Tata Steel bid

2018-07-17 moneycontrol
The National Company Law Appellate Tribunal on Tuesday stopped the lenders of Bhushan Power & Steel from voting on the resolution plan submitted by Tata Steel.
500470 TTST TATASTEEL TATLY 500228 JSWSTEEL

0
As Bhushan Power Steel lenders meet, operations creditors approach NCLT

2018-07-16 moneycontrol
Bhushan Power & Steel's Committee of Creditors will meet on Monday to take a call on the bids presented by Tata Steel and Liberty House.
AMKD 500228 BHUSANSTL 532727 AMTEKAUTO JSWSTEEL 500470 TTST TATASTEEL TATLY ADHUNIK 520077 500055

0
JSW Steel to focus on inorganic organic growth: Sajjan Jindal

2018-07-15 moneycontrol
Leading integrated steel manufacturer JSW Steel is looking at inorganic growth in both domestic and international markets as well as organic growth, to steer the company on its growth path, company chairman and managing director Sajjan Jindal said.
500228 BHUSANSTL JSWSTEEL 500055

0
Arfin India: Emerging smallcap riding value added aluminium products wave

2018-07-13 moneycontrol
In the business-to-business (B2B) segment it is difficult to win the hearts of customers particularly when products are commoditised. Taking up this challenge, Arfin India, which is into aluminium products, has consistently evolved its product categories through innovative techniques and research to stand tall in its category. During March, the company was conferred 'India’s Best Aluminium Products Manufacturing Company of the Year 2017' by IBC Infomedia, a division of International Brand Consulting Corporation, USA.
ARFIN RICOAUTO 539151 500039 520008 500228 BHUSANSTL 532508 539254 BANCOINDIA JSWSTEEL 500470 TTST TATASTEEL TATLY JSL 500055 ADANITRANS

0
AION Capital-JSW Steel consortium agrees to pay Monnet Ispat’s small creditors

2018-07-12 livemint
Mumbai: The AION Capital-JSW Steel consortium has agreed to pay small operational creditors of Monnet Ispat after the dedicated bankruptcy court observed that there is nothing for small vendors in the resolution plan and they need to keep them in mind while acquiring an asset at such an attractive valuation.
500228 JSWSTEEL

0
Hurting for Buyers, U.S. Coal Miners Are Learning to Love India - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
500228 JSWSTEEL

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...